Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Alzheimers Dement. 2018 Sep 25;14(11):1427–1437. doi: 10.1016/j.jalz.2018.06.3059

Table 2.

Baseline demographics; clinical characteristics; cognitive, biochemical, and imaging parameters in mutation carriers with high (i.e., ≥150 min/week) or low (i.e., <150 min/week) physical activity

Baseline characteristics High-active mutation carriers (n = 156) Low-active mutation carriers (n = 68) P value
Age (years) 37.3 (10.2) 41.1 (8.9) .0084
Estimated years till symptom onset −9.6 (8.4) − 5.3 (8.2) .0012
Gender (females, %) 84 (54%) 42 (62%) .272
Education (years) 14.1 (3.1) 13.8 (3.3) .496
Geriatric Depression Scale 2.1 (2.6) 2.5 (2.6) .252
MMSE 28.2 (2.5) 25.1 (6.4) <.0001
CDR global score 0.2 (0.3) 0.4 (0.4) .0002
CDR-SOB 0.7 (1.4) 2.0 (3.2) <.0001
Physical activity (min/week) 425.5 (159.2) 58.9 (52.4) <.0001
Global PIB-uptake 1.39 (0.3) 1.52 (0.5) .0539
CSF amyloid-β1–42 (pg/mL) 581.5 (305.2) 470.6 (259.2) .0178
CSF t-tau (pg/mL) 103.7 (67.1) 144.3 (106.9) .0019
CSF p-tau181 (pg/mL) 60.8 (35.6) 72.2 (42.0) .0296
t-tau/amyloid-β1–42 ratio 0.25 (0.2) 0.43 (0.4) .0002
p-tau/amyloid-β1–42 ratio 0.15 (0.1) 0.21 (0.2) .0146

Abbreviations: CDR, Clinical Dementia Rating scale; Global t-tau, total tau; MMSE, Mini Mental State Examination; PIB-uptake, global cerebral amyloid-b burden as measured by 11C-Pittsburgh Compound-B PET; p-tau, phosphorylated tau; SOB, Sum of Boxes.

NOTE. Data are given as mean (SD) or number (%). Significant differences are in bold.

NOTE. Mutation carriers with high physical activity reported 150 or more minutes of exercise per week, and mutation carriers with low physical activity reported less than 150 minutes per week of exercise.